We describe the development of quinolylnitrones(QNs)as multifunctional ligands inhibiting cholinesterases(ChEs:acetylcholinesterase and butyrylcholinesterase—h BChE)and monoamine oxidases(hMAO-A/B)for the therapy of ...
详细信息
We describe the development of quinolylnitrones(QNs)as multifunctional ligands inhibiting cholinesterases(ChEs:acetylcholinesterase and butyrylcholinesterase—h BChE)and monoamine oxidases(hMAO-A/B)for the therapy of neurodegenerative diseases.We identified QN 19,a simple,low molecular weight nitrone,that is readily synthesized from commercially available 8-hydroxyquinoline-2-carbaldehyde.Quinolylnitrone 19 has no typical pharmacophoric element to suggest ChE or MAO inhibition,yet unexpectedly showed potent inhibition of h BChE(IC50=1.06±0.31 nmol/L)and h MAO-B(IC_(50)=4.46±0.18μmol/L).The crystal structures of 19 with hBChE and hMAO-B provided the structural basis for potent binding,which was further studied by enzyme kinetics.Compound 19 acted as a free radical scavenger and biometal chelator,crossed the blood—brain barrier,was not cytotoxic,and showed neuroprotective properties in a 6-hydroxydopamine cell model of Parkinson's disease.In addition,in vivo studies showed the anti-amnesic effect of 19 in the scopolamine-induced mouse model of AD without adverse effects on motoric function and coordination.Importantly,chronic treatment of double transgenic APPswe-PS1δE9 mice with 19 reduced amyloid plaque load in the hippocampus and cortex of female mice,underscoring the disease-modifying effect of QN 19.
objective Alzheimer’s disease(AD) is a neurodegenerative disease characterized by progressive memory dysfunction and increasingly severe dementia. The most widely accepted hypothesis is that aggregation of β-amyl...
详细信息
objective Alzheimer’s disease(AD) is a neurodegenerative disease characterized by progressive memory dysfunction and increasingly severe dementia. The most widely accepted hypothesis is that aggregation of β-amyloid(Aβ) leads to a series of devastating effects to the nervous system, such as synaptic failure and neuronal death. The current drug development for AD therapy is mainly designed to antagonize Aβ, but the effect on cognition would be limited if the synaptic function is not restored. It is recently found that protein synthesis(m RNA translation) is impaired in AD brain, which leads to insufficient synthesis of critical proteins for synaptic function and neuronal survival. Therefore, identification of compounds that has the ability to enhance protein synthesis in neurons will be beneficial for the restoration of synaptic function and memory in AD. We previously found a compound C6, which induces robust protein synthesis in neuronal cell lines. This study aims to test whether this compound promotes synaptic function in hippocampal neurons, and whether it restores the synaptic and memory defects in AD modeled mice. Methods A puromycin labeling method was performed to test protein synthesis;Immunofluorescence and western-blot were used to test the expression of synaptic proteins;APP/PS1 transgenic mice, a widely accepted mouse model of AD, was used to test the treatment effect of C6;Novel object recognition test was used to test learning and memory of the mice. Results(1) C6 promoted de novo protein synthesis in hippocampal neurons;(2) C6 increased the expression of synapsin I and PSD95;(3) C6 promoted dendritic spine formation in hippocampal neurons which depended on translation;(4) C6 improved Novel object recognition in APP/PS1 mice. Conclusion C6, through upregulating protein synthesis, promotes synaptic function in cultured neurons and restores cognition functions in APP/PS1 mice.
暂无评论